Intellia Therapeutics Announces Publication of Positive Inte

Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single doseA single dose of NTLA-2002 led to 95% mean reduction

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Ian Karp , Alina Li , Matt Crenson , John Leonard , Drug Administration , Regulatory Agency , European Medicines Agency , European Commission , Intellia Therapeutics Inc , Corporate Communications , Clinical Program , European Academy Of Allergy , Nasdaq , Clinical Immunology Hybrid Congress , Exchange Commission , New England Journal , Intellia President , Chief Executive Officer , Clinical Immunology Hybrid , Orphan Drug , Innovation Passport , Priority Medicines , Orphan Drug Designation , Intellia Therapeutics , Private Securities Litigation Reform Act , Vice President , Investor Relations , Region ,